Close Menu

Silence Therapeutics said this week that it plans to raise as much as £5.7 million ($8.8 million) through the issuance of up to around 940 million new ordinary shares.

The issuance will come as a subscription of 840 million shares at £0.05 each to certain investors and directors, Silence said, and up to around 100 million shares through an open offer, also at £0.05 a share. The company also plans to issue a £1 million convertible loan note.

The proposed share price represents a roughly 44 percent discount to Silence's current share price as of July 11.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.

The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.

According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.